What C75 covers · when clinicians use it
ICD-10 code C75 identifies Malignant neoplasm of other endocrine glands and related structures in the U.S. ICD-10-CM clinical and billing record set. It sits within the Neoplasms chapter (C00–D49), the section that groups related diagnoses so providers, payers, and public-health agencies report them consistently. Clinicians and medical coders apply C75 when an encounter's findings match the Malignant neoplasm of other endocrine glands and related structures description, attaching it to the patient record so downstream insurance claims, payer audits, quality reporting, and epidemiological surveillance all reference the same standardized diagnosis. The ICD-10-CM is maintained by the Centers for Medicare & Medicaid Services and the CDC's National Center for Health Statistics, with an updated official code set released each U.S. fiscal year — always verify C75 against the current CMS/CDC release and your payer's documentation guidance before final use. This page summarizes documentation context for C75 and is a coding reference, not clinical, diagnostic, or billing advice.
C75 refers to Malignant neoplasm of other endocrine glands and related structures, a group of cancers arising from the hormone-secreting glands such as the thyroid, adrenal glands, or other endocrine tissues. These malignancies may affect hormone levels, cause systemic symptoms, and often require multidisciplinary management. ICD10 coding ensures clear classification, documentation, and appropriate treatment planning.
Symptoms
- Neck lump or swelling – Typical of thyroid cancers
- High blood pressure – Common in adrenal gland tumors
- Unexplained weight loss or gain – Due to hormone imbalance
- Palpitations or anxiety – From excess thyroid or adrenal hormones
- Fatigue and weakness – Often related to hormonal disruption
- Changes in appetite or mood – Caused by endocrine dysfunction
- Hoarseness or difficulty swallowing – In thyroid gland involvement
Diagnosis
Diagnosis of Malignant neoplasm of other endocrine glands and related structures involves hormonal assays, imaging studies (ultrasound, CT, MRI), nuclear medicine scans, and biopsy. Endocrinologists and oncologists collaborate to evaluate tumor type, hormonal activity, and malignancy potential. Genetic testing may also be relevant in hereditary syndromes.
ICD10 Code Usage
ICD10 code C75 is used in endocrinology, oncology, and surgery to classify endocrine malignancies. It supports insurance billing, cancer registry data entry, and outcome analysis, and helps guide targeted treatments such as hormone-suppressive therapies or surgery.
Related Codes
FAQs
Q1: What is ICD10 code C75?
A: This code documents Malignant neoplasm of other endocrine glands and related structures, a cancer affecting endocrine glands, in healthcare records and billing systems.
Q2: Are these cancers hormone-related?
A: Yes, they often disrupt normal hormone production, leading to metabolic or systemic symptoms.
Q3: Are they treatable?
A: Many endocrine cancers respond well to surgery, radioactive iodine, or hormone therapy, especially if detected early.
Q4: What is the prognosis?
A: Prognosis varies by tumor type and stage. Thyroid cancers often have excellent outcomes with early treatment.
Q5: Who treats these cancers?
A: Typically managed by a team including endocrinologists, oncologists, surgeons, and radiologists.
Conclusion
ICD10 code C75 plays a vital role in managing and documenting Malignant neoplasm of other endocrine glands and related structures. It helps healthcare professionals coordinate care, track outcomes, and guide treatment strategies. Proper coding ensures comprehensive reporting and enhances cancer research and patient support programs.